These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32031458)

  • 1. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
    Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory colitis associated with Teriflunomide.
    Esfahani NZ; von Geldern G; Romba MC; Parikh DA; Wundes A
    Mult Scler Relat Disord; 2020 Nov; 46():102480. PubMed ID: 32942118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide, a potential novel cause of chronic active colitis.
    Kővári B; Zachs J; Murchie B; Lauwers GY
    Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
    Bsteh G; Berger T
    Mult Scler; 2020 Nov; 26(13):1803-1804. PubMed ID: 32031463
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
    Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
    Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal pathologic findings of teriflunomide associated diarrhea.
    Fan JH; Fogt F; Berger JR
    Mult Scler Relat Disord; 2022 Feb; 58():103506. PubMed ID: 35066272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide: Pediatric First Approval.
    Paik J
    Paediatr Drugs; 2021 Nov; 23(6):609-613. PubMed ID: 34595696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebound syndrome in two cases of MS patients after teriflunomide cessation.
    Labauge P; Ayrignac X; Prin P; Charif M; Carra-Dalliere C
    Acta Neurol Belg; 2022 Oct; 122(5):1381-1384. PubMed ID: 35802339
    [No Abstract]   [Full Text] [Related]  

  • 11. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
    J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?
    Pourcher V; Yeung J; Le Pimpec-Barthes F; Maillart E; Gibault L; Boussouar S
    Rev Neurol (Paris); 2022 Mar; 178(3):266-267. PubMed ID: 34579947
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
    Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
    Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Camara-Lemarroy CR; Castilló J; Sastre-Garriga J; Tintore M; Montalban X
    Mult Scler; 2018 Sep; 24(10):1383-1385. PubMed ID: 29473796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study.
    Kusnirikova ZK; Kacirova I; Pesakova V; Hradilek P; Brozmanova H; Grundmann M
    J Neurol Sci; 2024 Mar; 458():122910. PubMed ID: 38309248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
    N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report.
    D'Aleo G; Rifici C; Donato A; Corallo F; Di Cara M; Bramanti P; Sessa E
    Medicine (Baltimore); 2020 Jul; 99(28):e21212. PubMed ID: 32664171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.